Video

Dr. Bajorin on Chemotherapy Approaches in Bladder Cancer

Author(s):

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Historically, bladder cancer has been treated with chemotherapy in metastatic and muscle-invasive disease, Bajorin says. In the metastatic setting, there are 2 standard chemotherapy regimens. For patients who are fit, in good physical condition, and have good renal function, cisplatin-based therapy is the standard approach. One regimen is MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) and the other is a combination of gemcitabine and cisplatin. Both treatments are considered interchangeable with regard to first-line therapy, he adds.

However, in a frailer and older patient population, kidney function can be compromised. Therefore, cisplatin is not possible in many of those patients, he explains. Because of this, carboplatin-based therapy has been the mainstay treatment. There have been randomized trials of carboplatin plus gemcitabine showing it as the best tolerated therapy and, in some patients, it can have a substantial benefit.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD